Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutation type, tyrosine kinase function in normal cell and tyrosine kinase inhibitor activity in cancers.

Scientific reports - 4 Mar 2026

Vanacker H, Cassier P A, Dufresne A, Pérol M, Verlingue Loic, Swalduz A, Vinceneux A, Attignon V, Brahmi M, Tredan O, Tirode F, Blay J -Y

Abstract excerpt

The clinical activity of tyrosine kinase inhibitors (TKI) varies across cancer types of cancers bearing similar receptor tyrosine kinase (RTK) mutations. Analyzing public databases, we tested the hypothesis that RTK function in normal cell could predict for TKI activity in the corresponding cancer. Classes of alterations for 16 RTK (missense mutations, amplifications, translocations) were analyzed in 17 different...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Mutation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mutation, Missense

Share to Neoplasms

Share to Protein Kinase Inhibitors

Share to Protein-Tyrosine Kinases

Share to Receptor Protein-Tyrosine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 41781442
DOI: 10.1038/s41598-026-41710-0
PMCID: PMC13068889

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Nov 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutation type, tyrosine kinase function in normal cell and tyrosine kinase inhibitor activity in cancers.PMID 41781442Read ↗

Comparison of actionable alterations in cancers with kinase fusion, mutation, and amplificationSemantic proximity Read ↗

Receptor Tyrosine Kinase-Targeted Cancer TherapySemantic proximity Read ↗

Comparison of actionable alterations in cancers with kinase fusion, mutation, and copy number alteration.Semantic proximity Read ↗

Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan-cancer analysis.Semantic proximity Read ↗

TRKing down an old oncogene in a new era of targeted therapy.Semantic proximity Read ↗

Landscape of potentially targetable receptor tyrosine kinase fusions in diverse cancers by DNA-based profilingSemantic proximity Read ↗

Systematic Pan-cancer Functional Inference and Validation of Hyper, Hypo and Neomorphic MutationsSemantic proximity Read ↗

TRK Inhibition: A New Tumor-Agnostic Treatment StrategySemantic proximity Read ↗

Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors.Semantic proximity Read ↗

TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations.Semantic proximity Read ↗

Receptor tyrosine kinases: biological functions and anticancer targeted therapySemantic proximity Read ↗

Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.